RE:Trial Result Tables
Eoganacht wrote: Below are 3 trial result tables.None of the 3 tables include the phase 1 patients as it looks like Theralase will be presenting trial data without them from now on.
The first is from the ASCO presentation (29 Nov 22 results) but with the phase 1 patients removed.
The second is derived from the AUA presentation table and Swimmer's Plot. It includes the CR patients so that the ASCO results and AUA results can be compared.
The third is the same as the AUA table but with the first 12 undertreated patients removed. I believe this table most accurately reflects the efficacy of the treatment.
| Assessed | 90 Days | 180 Days | 270 Days | 360 Days | 350 Days |
| | % | # | % | # | % | # | % | # | % | # |
| CR | 53% | 21 | 43% | 15 | 38% | 13 | 26% | 8 | 23% | 6 |
| IR | 15% | 6 | 26% | 9 | 21% | 7 | 16% | 5 | 12% | 3 |
| TR | 68% | 27 | 69% | 24 | 59% | 20 | 42% | 13 | 35% | 9 |
| NR | 32% | 13 | 31% | 11 | 41% | 14 | 58% | 18 | 65% | 17 |
| Evaluable | 40 | 35 | 34 | 31 | 26 |
Results from ASCO Presentation minus phase 1 patients | Assessed | 90 Days | 180 Days | 270 Days | 360 Days | 350 Days |
| | % | # | % | # | % | # | % | # | % | # |
| CR | 54% | 28 | 49% | 23 | 38% | 15 | 24% | 9 | 22% | 8 |
| IR | 12% | 6 | 17% | 8 | 15% | 6 | 5% | 2 | 5% | 2 |
| TR | 65% | 34 | 66% | 31 | 53% | 21 | 29% | 11 | 27% | 10 |
| NR | 35% | 18 | 34% | 16 | 47% | 19 | 71% | 27 | 73% | 27 |
| Evaluable | 52 | 47 | 40 | 38 | 37 |
Results from AUA Presentation including CR patients | Assessed | 90 Days | 180 Days | 270 Days | 360 Days | 350 Days |
| | % | # | % | # | % | # | % | # | % | # |
| CR | 70% | 28 | 66% | 23 | 54% | 15 | 35% | 9 | 32% | 8 |
| IR | 15% | 6 | 23% | 8 | 21% | 6 | 8% | 2 | 8% | 2 |
| TR | 85% | 34 | 89% | 31 | 75% | 21 | 42% | 11 | 40% | 10 |
| NR | 15% | 6 | 11% | 4 | 25% | 7 | 58% | 15 | 60% | 15 |
| Evaluable | 40 | 35 | 28 | 26 | 25 |
Results from AUA Presentation including CR patients with the 12 undertreated patients removed
Thanks Eoganacht....
When I look at the 4/26 Swimmer plot, there are 13 active patients (at different stages) who have been assessed at 90 days, plan to move forward with the trial & are awaiting their 360 day assessment. Interestingly, 2 patients who had CR through 90 & 180 days are represented as currently being inactive. For the above subgroup of 13 patients, 11 of 13 (85%) are CR thus far. There are 3 awaiting their 180 day assessment & 7 of the 11 have maintained a CR for at least 180 days.
Imo, the current high CR%s of the above block of patients should bode very well for our future 450 day data. Based on our historical durable responses, it's not unreasonable to conclude that 6 or more of those above 11 will maintain CR at 450 days. This would lead to ~14 of 40 CRs (35% CR) at 450 days. Even if you consider 2 of the 8 CRs at 450 days representing the the first 12 treated (& therefore discounted), you would still have a 450 day CR rate of 30%...still good. All imo.